1zro: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
==Crystal structure of EBA-175 Region II (RII) crystallized in the presence of (alpha)2,3-sialyllactose== | ==Crystal structure of EBA-175 Region II (RII) crystallized in the presence of (alpha)2,3-sialyllactose== | ||
<StructureSection load='1zro' size='340' side='right' caption='[[1zro]], [[Resolution|resolution]] 2.25Å' scene=''> | <StructureSection load='1zro' size='340' side='right'caption='[[1zro]], [[Resolution|resolution]] 2.25Å' scene=''> | ||
== Structural highlights == | == Structural highlights == | ||
<table><tr><td colspan='2'>[[1zro]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Plafa Plafa]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1ZRO OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=1ZRO FirstGlance]. <br> | <table><tr><td colspan='2'>[[1zro]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Plafa Plafa]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=1ZRO OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=1ZRO FirstGlance]. <br> | ||
| Line 27: | Line 27: | ||
</div> | </div> | ||
<div class="pdbe-citations 1zro" style="background-color:#fffaf0;"></div> | <div class="pdbe-citations 1zro" style="background-color:#fffaf0;"></div> | ||
==See Also== | |||
*[[Erythrocyte binding antigen|Erythrocyte binding antigen]] | |||
== References == | == References == | ||
<references/> | <references/> | ||
__TOC__ | __TOC__ | ||
</StructureSection> | </StructureSection> | ||
[[Category: Large Structures]] | |||
[[Category: Plafa]] | [[Category: Plafa]] | ||
[[Category: Enemark, E J]] | [[Category: Enemark, E J]] | ||
Revision as of 12:35, 5 February 2020
Crystal structure of EBA-175 Region II (RII) crystallized in the presence of (alpha)2,3-sialyllactoseCrystal structure of EBA-175 Region II (RII) crystallized in the presence of (alpha)2,3-sialyllactose
Structural highlights
Evolutionary Conservation Check, as determined by ConSurfDB. You may read the explanation of the method and the full data available from ConSurf. Publication Abstract from PubMedErythrocyte binding antigen 175 (EBA-175) is a P. falciparum protein that binds the major glycoprotein found on human erythrocytes, glycophorin A, during invasion. Here we present the crystal structure of the erythrocyte binding domain of EBA-175, RII, which has been established as a vaccine candidate. Binding sites for the heavily sialylated receptor glycophorin A are proposed based on a complex of RII with a glycan that contains the essential components required for binding. The dimeric organization of RII displays two prominent channels that contain four of the six observed glycan binding sites. Each monomer consists of two Duffy binding-like (DBL) domains (F1 and F2). F2 more prominently lines the channels and makes the majority of the glycan contacts, underscoring its role in cytoadherence and in antigenic variation in malaria. Our studies provide insight into the mechanism of erythrocyte invasion by the malaria parasite and aid in rational drug design and vaccines. Structural basis for the EBA-175 erythrocyte invasion pathway of the malaria parasite Plasmodium falciparum.,Tolia NH, Enemark EJ, Sim BK, Joshua-Tor L Cell. 2005 Jul 29;122(2):183-93. PMID:16051144[1] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
| ||||||||||||||||||
